Because the IL-8–CXCR1/2 signaling axis is involved not only in inflammatory diseases, including IBD, but also in carcinogenesis, its antagonists have been used as novel therapeutic targets for gastrointestinal tract inflammatory and malignant processes in clinical trials [34]. The gene discussed is CXCR1; the disease is inflammatory bowel disease.